Circio to participate in the Annual European Life Sciences CEO Forum in Zürich

Oslo, Norway, 27 February 2024 – Circio Holding ASA (OSE: CRNA) announces that CFO Lubor Gaal is invited as a panel discussant at the 17th Annual European Life Sciences CEO Forum

Dr Lubor Gaal will participate in the conference discussion panel on gene therapy in rare disease:

17th Annual European Life Sciences CEO Forum, Zurich, Switzerland
Panel: Rare & Orphan Therapies Panel: Gene Therapy & Other Modalities
Presenter: Lubor Gaal, CFO
Date: 28 February 2024
Time: 11:50 CET


For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536

Renate Birkeli, Investor Relations
Phone: +47 922 61 624

About Circio

Building next generation RNA therapeutics

Circio Holding ASA is a biotechnology company developing novel circular RNA and immunotherapy medicines.

Circio has established a unique circular RNA (circRNA) platform to develop novel circRNA medicines for rare disease, vaccines, and cancer. The proprietary circVec technology is based on a modular genetic cassette design for efficient biogenesis of multifunctional circRNA from DNA and viral vectors, which can be deployed for many purposes. The circVec platform has demonstrated enhanced and more durable protein expression than classic mRNA vector systems, and has the potential to become the new gold-standard for DNA and virus-based therapeutics in the future. The circRNA R&D activities are being conducted by the wholly owned subsidiary Circio AB based at the Karolinska Institute in Stockholm, Sweden.

In addition, Circio is developing a cancer vaccine, TG01, targeting KRAS driver mutations. TG01 is currently being tested in three clinical trials: RAS-mutated pancreatic cancer and lung and non-resectable pancreatic cancer in US, and multiple myeloma in Norway. These studies are being run through academic collaborative networks, supported by prestigious research grants from Innovation Norway and the Norwegian Research Council, creating read-outs and future optionality for the program at low cost to Circio.